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https://Implementation of new endovenous treatments in therapy for
lateral embryonic veinsUlrike Huegel, MD, and Iris Baumgartner, MD, Bern, SwitzerlandABSTRACT
Klippel-Trénaunay syndrome is characterized by a persistent lateral embryonic vein. This so-called marginal vein has a
large diameter causing venous stasis and venous hypertension because of the absence of valves along its entire length.
The extensive diameter of the vein impedes successful treatment by sclerotherapy. Surgical removal is considered
technically challenging for potential severe intraoperative blood loss due to the large perforators to the deep veins. Here
we show that endovenous treatments (laser ablation, cyanoacrylate adhesive) might be feasible options in therapy for
lateral embryonic veins. (J Vasc Surg Cases and Innovative Techniques 2019;5:243-7.)
Keywords: Klippel-Trénaunay syndrome; Marginal vein; Endovenous laser; CyanoacrylateThe Klippel-Trénaunay syndrome (KTS) was ﬁrst
described in 1900by the FrenchphysiciansMauriceKlippel
and Paul Trénaunay.1 More than a century later, the
eponym has been attached to a rare, complex malforma-
tion characterized by the clinical triad of capillary malfor-
mations, soft tissue and bone hypertrophy, and atypical,
mostly lateral varicosity. As concomitant phenomena,
deep inﬁltrating venousmalformations, deep vein anoma-
lies, and lymphedemahave also been described. The etiol-
ogy of KTS is unknown; it is likely due to a mesodermal
abnormality that occurs during early fetal development.2
At the beginning of the ﬁrst embryonic phase, the venous
outﬂow from the primitive lower limb occurs through a
lateral ﬁbular vein into the posterior cardinal vein. In the
second stage, an anteriormedial tibial vein appears, which
becomes the main draining vein of the calf, whereas the
lateral ﬁbular vein moves posteriorly. With a defect at this
stage, the lateral ﬁbular vein will persist and become the
marginal vein.3 The marginal vein is usually thick walled; it
is located immediately under the skin, and it is incompe-
tent along its entire length because of the absence of
valves. Drainage is either into a lateral branch of the
profunda femoris vein or into the internal iliac vein. The
vein sometimes crosses anterior in the thigh and joins
the femoral vein next to the great saphenous vein.2
Indications for treatment of amarginal vein include hem-
orrhage, infections, thromboembolism, pain, heaviness,he Department of Angiology, Swiss Cardiovascular Center, Inselspital,
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In the case of limb length discrepancy in childhood, treat-
ment is also recommended to achieve length discrepancy
correction.2,4 The management of the marginal vein has
been largely conservative, and compression therapy was
the mainstay.2
In the case of symptomatic marginal veins, surgery was
the classic therapy in the past. The marginal veins may
have large perforators to the deep veins; therefore, closed
stripping should be avoided because of the risk of exces-
sive bleeding and hematomas.5 The surgical excision is
technically demanding. Because of intradermal exten-
sion, the veins could tear easily and provoke serious
bleeding. Sclerotherapy with ethanol, sodium tetradecyl
sulfate, and polidocanol foam has also been used. These
agents cause endothelial damage, inﬂammation, throm-
bosis, and ﬁbrosis that ultimately obliterate the vascular
channels. At last, all sclerosants become diluted by blood
and are rendered ineffective.6 Herein we see the main
limitation of sclerotherapy in the treatment of marginal
veins because their great volumes cause quick dilution
of the sclerosant and therefore impede effective destruc-
tion of the vessel endothelium. Another limitation of
sclerotherapy is the risk of causing deep venous throm-
bosis by extension of the sclerosant into the deep venous
system over the numerous perforators.
Thermoablative techniques such as laser and radiofre-
quency have demonstrated efﬁcacy in the treatment of
varicose veins since the late 1990s.7 Their use in therapy for
marginal veins is viewed critically because of their wide
lumen and the location immediately under the skin.2 A
few case reports on endothermal ablation of the marginal
vein inchildrenhavealreadybeenpublished.8-10Using large
quantitiesof tumescentanesthesiawithultrasoundveriﬁca-
tion of skin separation, endovenous laser might be an
efﬁcient treatment option. In the case of tortuous marginal
veins with great numbers of tributaries, n-butyl cyanoacry-
late embolotherapy might be a feasible alternative.
The patients provided written informed consent to the
publication.243
Fig 1. Case 1. Magnetic resonance imaging showing the
ectatic marginal vein (arrows) in the lateral aspect of the
lower limb before endovenous laser ablation.
Fig 2. Case 1. Clinical aspect 20 months after endovenous
laser ablation indicating a discrete brown stain at the
former course of the marginal vein (arrows).
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Fig 3. Case 2. Thermography of the lower limb depicting
tortuous marginal vein with multiple tributaries.
Fig 4. Case 3. Ultrasound of occluded marginal vein
3 weeks after treatment with n-butyl cyanoacrylate.
Journal of Vascular Surgery Cases and Innovative Techniques Huegel and Baumgartner 245
Volume 5, Number 3CASE REPORT
Case 1. Wereport thecaseof a 31-year-oldwomanwithKTSand
a protruding large lateral embryonic vein on the left leg with a
maximal diameter of 1.4 cm (Fig 1) and discomfort due to venous
stasis with limb swelling while standing. Because of a localized
intravascular coagulopathy, the patient was treated with an oral
anticoagulant in prophylactic dosage. Besides swelling, no other
clinical signs of chronic venous insufﬁciency were apparent. On
the right leg, lymphedema and a capillary malformation were
present. In the past, the patient had been treated unsuccessfully
with repeated ethanol injections. Because of the high venousvolume, the ethanol was quickly diluted and did not cause
effective cellular damage to the endothelial layer to induce
thrombosis and vascular occlusion. Toocclude the vein,weuseda
diode laser with a wavelength of 1470 nm at a setting of 10 W
(VenaCure Laser 1470; AngioDynamics, Latham,NY)with a total of
13,900 J over 76 cm (180 J/cm). Puncture of the vein was realized
under ultrasound guidance using a 14-gauge peripheral intrave-
nous catheter. Thenearest distancebetween the skin surface and
vein was 3.5 mm. The laser ﬁber (NeverTouch Direct; AngioDy-
namics)wasadvancedover thecomplete subcutaneous lengthof
thevein fromtheankle to thehip.After tumescentanesthesiawas
applied, the laser was activated and pulled back continuously
witha velocity of 1 cmper8 seconds. Each segmentwaspassedby
the laser ﬁber repetitively until the ﬁber could no longer be
advanced, so indicating closure of the vein. An ultrasound control
after 20 months revealed continued success with complete
closure of the treated vein segments. At clinical examination, only
a discrete brown stain indicated the former course of the vein
(Fig 2). Thepatient reporteda reductionof swellingandheaviness.
Case 2. A 47-year-old woman with a painful lateral embryonic
vein of 8 mm in maximal diameter and multiple subcutaneous
tributaries (Fig 3), soft tissue hypertrophy, leg length difference,
and extended capillary malformation of the left leg was treated
with n-butyl cyanoacrylate (VenaSeal; Medtronic, Minneapolis,
Minn). The medical adhesive was injected through a 5F catheter
for the straight parts of the vein and through an 18- or 20-gauge
peripheral intravenous catheter in the tributaries. A total quan-
tity of 9 mL of n-butyl cyanoacrylate was injected in two treat-
ment sessions. Because of an antiphospholipid syndrome, the
patient is receiving oral anticoagulation, which did not have to
be stopped for the procedure. The ultrasound control after
26 months indicated therapeutic success with complete closure
of the treated vein segments. A reduction of swelling and pain
was achieved.
Case 3. A 16-year-old boy with incomplete KTS was suffering
from swelling of the left leg and was disturbed by a large mar-
ginal vein with a diameter of 10 mm and multiple protruding
tributaries. No other signs of chronic venous insufﬁciency were
present.
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was applied. The procedures were performed under sterile con-
ditions. The adhesive was injected through an 18- or 20-gauge
peripheral intravenous catheter. No anticoagulation was used
during the procedure or in the follow-up. The ultrasound control
after 26 months indicated therapeutic success with complete
closure of the treated vein segments (Fig 4). Besides reduction
of swelling, the patient proﬁted from the decrease of the
cosmetically disturbing veins.
DISCUSSION
The literature to date has demonstrated that endove-
nous laser ablation is effective and safe in the treatment
of great saphenous veins.11 There is a paucity of reports
using endovenous laser ablation for treatment of the
marginal vein in KTS. Three reports with a total of 13
patients demonstrated good results.8-10 Some authors
do not recommend laser closure of the vein because of
the risk of skin burns and uncomfortable scarring.5 In
our experience, these side effects can often be avoided
with a correctly applied and large enough volume of
tumescent anesthesia. In contrast to the great saphe-
nous vein, embryonic marginal veins are not surrounded
by a fascial envelope; when ﬂuid is injected around the
vein, there is a quick dispersion, so that the ﬂuid has to
be reinjected to maintain a sufﬁcient “isolating sheath.”
Nevertheless, the current thermoablative techniques
will not be applicable to themanagement of all marginal
veins because of their extremely superﬁcial location right
beneath the skin. This anatomic peculiarity in combina-
tion with a thin dermis bears a high risk of heat damage
of the skin.12
For those tortuous marginal veins with intradermal
extension that were not suitable for thermoablative tech-
niques or ethanol because of the risk of skin necrosis, we
introduced n-butyl cyanoacrylate. We chose this sclero-
sant because in our experience, sclerosants like polidoca-
nol and sodium tetradecyl sulfate are not effective
enough to destroy the vessel endothelium of these
embryonic veins.
In our two cases, we used n-butyl cyanoacrylate after a
surgical intervention was not considered the optimal
treatment because of high bleeding risk due to the in-
tradermal extension and to avoid scarring of these
young patients. Sclerotherapy with ethanol was also
declined because of the risk of skin necrosis. In the
treatment of truncal varicosity, n-butyl cyanoacrylate
has already proved its efﬁciency and safety.13,14 On intra-
venous administration, it elicits a granulomatous
foreign body reaction and a concomitant inﬂammatory
vein wall reaction, leading to subsequent ﬁbrotic degra-
dation.15 No tumescent anesthesia is necessary for this
procedure.
Using endovenous laser ablation in the case of a mar-
ginal vein with large diameter, straight course, and suf-
ﬁcient distance to the skin and n-butyl cyanoacrylate intwo cases with marginal veins of small caliber, tortuous
courses, multiple subcutaneous tributaries, and intra-
dermal extension, we reached good results with com-
plete closure of the marginal vein conﬁrmed by
ultrasound. We deﬁned a complete closure as no
discrete segment of patency >5 cm. The procedures
were not mixed with phlebectomies or foam sclerother-
apy. All patients had a subjective reduction of swelling
and heaviness of the treated legs. Whereas we saw
skin staining after our laser procedure, no discoloration
appeared after n-butyl cyanoacrylate, but the adhesive
remained palpable. No thrombosis or pulmonary em-
bolism occurred.CONCLUSIONS
Endovenous laser ablation and the medical adhesive
n-butyl cyanoacrylate (VenaSeal) seem to be effective in
treatment of the marginal vein in KTS during short-
term follow-up. Our ﬁndings so far are encouraging, but
more experience is needed to recommend these new
treatment modalities in congenital vascular malforma-
tions such as KTS.REFERENCES
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